Fezolinetant Disease Interactions

Fezolinetant is contraindicated in patients with known cirrhosis and has not been studied in patients with Child-Pugh C hepatic impairment. Drug exposure is increased in patients with Child-Pugh A or B hepatic impairment. Fezolinetant may increase serum transaminase levels and drug-induced liver injury has been reported within 40 days of initiation. Assess liver function at baseline, monthly for the first 3 months, then at 6 and 9 months of therapy, or if symptoms of liver injury occur. Do not initiate therapy if ALT, AST, or total bilirubin is 2 times the upper limit of normal or greater. Treatment discontinuation may be required if transaminase elevations occur.

Fezolinetant is contraindicated in patients with severe renal impairment or end-stage renal disease. Avoid use in patients with an estimated GFR less than 30 mL/min/1.73 m2.